{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:28:37Z","timestamp":1792528117470,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072712"],"award-info":[{"award-number":["82072712"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471706"],"award-info":[{"award-number":["82471706"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002860","name":"China Sponsorship Council","doi-asserted-by":"publisher","award":["202408320405"],"award-info":[{"award-number":["202408320405"]}],"id":[{"id":"10.13039\/501100002860","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M761236"],"award-info":[{"award-number":["2024M761236"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20240487"],"award-info":[{"award-number":["BK20240487"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08115-z","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T10:35:56Z","timestamp":1777026956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PFDN5 synergizes with anti-PD1 therapy to promote triple-negative breast cancer cell death through JAK2\/STAT3\/c-Myc signaling axis"],"prefix":"10.1186","volume":"24","author":[{"given":"Xiao-Ren","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Lluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Qi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Peng","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Jing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1453-8664","authenticated-orcid":false,"given":"Min-Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"8115_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"8115_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15:121.","journal-title":"J Hematol Oncol"},{"key":"8115_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-023-02677-x","volume":"30","author":"Z Jiang","year":"2024","unstructured":"Jiang Z, Ouyang Q, Sun T, Zhang Q, Teng Y, Cui J, et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nat Med. 2024;30:249\u201356.","journal-title":"Nat Med"},{"key":"8115_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","volume":"293","author":"P Kumar","year":"2016","unstructured":"Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016;293:247\u201369.","journal-title":"Arch Gynecol Obstet"},{"key":"8115_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","volume":"16","author":"S Zhu","year":"2023","unstructured":"Zhu S, Wu Y, Song B, Yi M, Yan Y, Mei Q, et al. Recent advances in targeted strategies for triple-negative breast cancer. J Hematol Oncol. 2023;16:100.","journal-title":"J Hematol Oncol"},{"key":"8115_CR6","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou C, Sonzogni O, De Oliveria Taveira M, Mehta AK, Kothari A, Wang D, et al. PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. Cancer Discov. 2019;9:722\u201337.","journal-title":"Cancer Discov"},{"key":"8115_CR7","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","volume":"35","author":"A Bardia","year":"2017","unstructured":"Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, et al. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2017;35:2141\u20138.","journal-title":"J Clin Oncol"},{"key":"8115_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-biochem-060208-092442","volume":"82","author":"YE Kim","year":"2013","unstructured":"Kim YE, Hipp MS, Bracher A, Hayer-Hartl M, Hartl FU. Molecular chaperone functions in protein folding and proteostasis. Annu Rev Biochem. 2013;82:323\u201355.","journal-title":"Annu Rev Biochem"},{"key":"8115_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.semcancer.2021.07.002","volume":"76","author":"I Masgras","year":"2021","unstructured":"Masgras I, Laquatra C, Cannino G, Serapian SA, Colombo G, Rasola A. The molecular chaperone TRAP1 in cancer: From the basics of biology to pharmacological targeting. Semin Cancer Biol. 2021;76:45\u201353.","journal-title":"Semin Cancer Biol"},{"key":"8115_CR10","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.apsb.2020.01.018","volume":"10","author":"L Wang","year":"2020","unstructured":"Wang L, Xu X, Jiang Z, You Q. Modulation of protein fate decision by small molecules: targeting molecular chaperone machinery. Acta Pharm Sin B. 2020;10:1904\u201325.","journal-title":"Acta Pharm Sin B"},{"key":"8115_CR11","doi-asserted-by":"publisher","first-page":"6730","DOI":"10.1093\/emboj\/18.23.6730","volume":"18","author":"MR Leroux","year":"1999","unstructured":"Leroux MR, Fandrich M, Klunker D, Siegers K, Lupas AN, Brown JR, et al. MtGimC, a novel archaeal chaperone related to the eukaryotic chaperonin cofactor GimC\/prefoldin. EMBO J. 1999;18:6730\u201343.","journal-title":"EMBO J"},{"key":"8115_CR12","doi-asserted-by":"publisher","first-page":"816214","DOI":"10.3389\/fcell.2021.816214","volume":"9","author":"I Tahmaz","year":"2021","unstructured":"Tahmaz I, Shahmoradi Ghahe S, Topf U. Prefoldin Function in Cellular Protein Homeostasis and Human Diseases. Front Cell Dev Biol. 2021;9:816214.","journal-title":"Front Cell Dev Biol"},{"key":"8115_CR13","doi-asserted-by":"publisher","first-page":"8847","DOI":"10.2147\/CMAR.S270237","volume":"12","author":"SJ Mo","year":"2020","unstructured":"Mo SJ, Zhao HC, Tian YZ, Zhao HL. The Role of Prefoldin and Its Subunits in Tumors and Their Application Prospects in Nanomedicine. Cancer Manag Res. 2020;12:8847\u201356.","journal-title":"Cancer Manag Res"},{"key":"8115_CR14","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.tibs.2009.12.007","volume":"35","author":"VF Lundin","year":"2010","unstructured":"Lundin VF, Leroux MR, Stirling PC. Quality control of cytoskeletal proteins and human disease. Trends Biochem Sci. 2010;35:288\u201397.","journal-title":"Trends Biochem Sci"},{"key":"8115_CR15","doi-asserted-by":"publisher","first-page":"46562","DOI":"10.1074\/jbc.M104937200","volume":"276","author":"A Satou","year":"2001","unstructured":"Satou A, Taira T, Iguchi-Ariga SM, Ariga H. A novel transrepression pathway of c-Myc. Recruitment of a transcriptional corepressor complex to c-Myc by MM-1, a c-Myc-binding protein. J Biol Chem. 2001;276:46562\u20137.","journal-title":"J Biol Chem"},{"key":"8115_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fneur.2020.00233","volume":"11","author":"Y Tao","year":"2020","unstructured":"Tao Y, Han Y, Yu L, Wang Q, Leng SX, Zhang H. The Predicted Key Molecules, Functions, and Pathways That Bridge Mild Cognitive Impairment (MCI) and Alzheimer\u2019s Disease (AD). Front Neurol. 2020;11:233.","journal-title":"Front Neurol"},{"key":"8115_CR17","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3389\/fimmu.2019.00384","volume":"10","author":"OC Kwon","year":"2019","unstructured":"Kwon OC, Lee EJ, Lee JY, Youn J, Kim TH, Hong S, et al. Prefoldin 5 and Anti-prefoldin 5 Antibodies as Biomarkers for Uveitis in Ankylosing Spondylitis. Front Immunol. 2019;10:384.","journal-title":"Front Immunol"},{"key":"8115_CR18","doi-asserted-by":"publisher","first-page":"45137","DOI":"10.1074\/jbc.M106127200","volume":"276","author":"Y Fujioka","year":"2001","unstructured":"Fujioka Y, Taira T, Maeda Y, Tanaka S, Nishihara H, Iguchi-Ariga SM, et al. MM-1, a c-Myc-binding protein, is a candidate for a tumor suppressor in leukemia\/lymphoma and tongue cancer. J Biol Chem. 2001;276:45137\u201344.","journal-title":"J Biol Chem"},{"key":"8115_CR19","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/gcc.20316","volume":"45","author":"GS Guimaraes","year":"2006","unstructured":"Guimaraes GS, Latini FR, Camacho CP, Maciel RM, Dias-Neto E, Cerutti JM. Identification of candidates for tumor-specific alternative splicing in the thyroid. Genes Chromosomes Cancer. 2006;45:540\u201353.","journal-title":"Genes Chromosomes Cancer"},{"key":"8115_CR20","doi-asserted-by":"publisher","first-page":"e0131280","DOI":"10.1371\/journal.pone.0131280","volume":"10","author":"S Hennecke","year":"2015","unstructured":"Hennecke S, Beck J, Bornemann-Kolatzki K, Neumann S, Murua Escobar H, Nolte I, et al. Prevalence of the Prefoldin Subunit 5 Gene Deletion in Canine Mammary Tumors. PLoS ONE. 2015;10:e0131280.","journal-title":"PLoS ONE"},{"key":"8115_CR21","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.yexcr.2008.01.002","volume":"314","author":"T Yoshida","year":"2008","unstructured":"Yoshida T, Kitaura H, Hagio Y, Sato T, Iguchi-Ariga SM, Ariga H. Negative regulation of the Wnt signal by MM-1 through inhibiting expression of the wnt4 gene. Exp Cell Res. 2008;314:1217\u201328.","journal-title":"Exp Cell Res"},{"key":"8115_CR22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.clbc.2022.04.001","volume":"22","author":"MN Uddin","year":"2022","unstructured":"Uddin MN, Wang X. Identification of Breast Cancer Subtypes Based on Gene Expression Profiles in Breast Cancer Stroma. Clin Breast Cancer. 2022;22:521\u201337.","journal-title":"Clin Breast Cancer"},{"key":"8115_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","volume":"25","author":"DS Chandrashekar","year":"2022","unstructured":"Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, et al. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18\u201327.","journal-title":"Neoplasia"},{"key":"8115_CR24","doi-asserted-by":"publisher","first-page":"e27633","DOI":"10.2196\/27633","volume":"23","author":"A Lanczky","year":"2021","unstructured":"Lanczky A, Gyorffy B. Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation. J Med Internet Res. 2021;23:e27633.","journal-title":"J Med Internet Res"},{"key":"8115_CR25","doi-asserted-by":"publisher","first-page":"D956","DOI":"10.1093\/nar\/gkx1090","volume":"46","author":"SV Vasaikar","year":"2018","unstructured":"Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46:D956\u201363.","journal-title":"Nucleic Acids Res"},{"key":"8115_CR26","doi-asserted-by":"crossref","unstructured":"Chen J, Liu W, Luo T, Yu Z, Jiang M, Wen J, et al. A comprehensive comparison on cell-type composition inference for spatial transcriptomics data. Brief Bioinform. 2022;23.","DOI":"10.1093\/bib\/bbac245"},{"key":"8115_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00129039-200403000-00002","volume":"12","author":"S Umemura","year":"2004","unstructured":"Umemura S, Itoh J, Itoh H, Serizawa A, Saito Y, Suzuki Y, et al. Immunohistochemical evaluation of hormone receptors in breast cancer: which scoring system is suitable for highly sensitive procedures? Appl Immunohistochem Mol Morphol. 2004;12:8\u201313.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"8115_CR28","doi-asserted-by":"publisher","first-page":"eabn6928","DOI":"10.1126\/sciadv.abn6928","volume":"8","author":"J Yao","year":"2022","unstructured":"Yao J, Wu XY, Yu Q, Yang SF, Yuan J, Zhang ZQ, et al. The requirement of phosphoenolpyruvate carboxykinase 1 for angiogenesis in vitro and in vivo. Sci Adv. 2022;8:eabn6928.","journal-title":"Sci Adv"},{"key":"8115_CR29","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41419-021-04201-w","volume":"12","author":"XR Zhu","year":"2021","unstructured":"Zhu XR, Peng SQ, Wang L, Chen XY, Feng CX, Liu YY, et al. Identification of phosphoenolpyruvate carboxykinase 1 as a potential therapeutic target for pancreatic cancer. Cell Death Dis. 2021;12:918.","journal-title":"Cell Death Dis"},{"key":"8115_CR30","doi-asserted-by":"publisher","first-page":"972744","DOI":"10.3389\/fonc.2022.972744","volume":"12","author":"XR Zhu","year":"2022","unstructured":"Zhu XR, Zhu JQ, Chen YF, Liu YY, Lu JJ, Sun J, et al. Bioinformatics analysis and experimental verification of the prognostic and biological significance mediated by fatty acid metabolism related genes for hepatocellular carcinoma. Front Oncol. 2022;12:972744.","journal-title":"Front Oncol"},{"key":"8115_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41419-023-05684-5","volume":"14","author":"SQ Peng","year":"2023","unstructured":"Peng SQ, Zhu XR, Zhao MZ, Zhang YF, Wang AR, Chen MB, et al. Identification of matrix-remodeling associated 5 as a possible molecular oncotarget of pancreatic cancer. Cell Death Dis. 2023;14:157.","journal-title":"Cell Death Dis"},{"key":"8115_CR32","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/s41419-022-05501-5","volume":"13","author":"J Lu","year":"2022","unstructured":"Lu J, Liu Q, Zhu L, Liu Y, Zhu X, Peng S, et al. Endothelial cell-specific molecule 1 drives cervical cancer progression. Cell Death Dis. 2022;13:1043.","journal-title":"Cell Death Dis"},{"key":"8115_CR33","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41420-023-01679-5","volume":"9","author":"F Cheng","year":"2023","unstructured":"Cheng F, Tang YF, Cao Y, Peng SQ, Zhu XR, Sun Y, et al. KCNAB2 overexpression inhibits human non-small-cell lung cancer cell growth in vitro and in vivo. Cell Death Discov. 2023;9:382.","journal-title":"Cell Death Discov"},{"key":"8115_CR34","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41419-025-07410-9","volume":"16","author":"XR Zhu","year":"2025","unstructured":"Zhu XR, Zhu JQ, Gu QH, Liu N, Lu JJ, Li XH, et al. A novel identified epithelial ligand-receptor-associated gene signature highlights POPDC3 as a potential therapy target for non-small cell lung cancer. Cell Death Dis. 2025;16:114.","journal-title":"Cell Death Dis"},{"key":"8115_CR35","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41419-024-07079-6","volume":"15","author":"JZ Jiang","year":"2024","unstructured":"Jiang JZ, Qiao YB, Zhu XR, Gu QH, Lu JJ, Ye ZY, et al. Identification of Galphai3 as a promising molecular oncotarget of pancreatic cancer. Cell Death Dis. 2024;15:699.","journal-title":"Cell Death Dis"},{"key":"8115_CR36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12935-024-03457-4","volume":"24","author":"J Zhu","year":"2024","unstructured":"Zhu J, Zhu X, Shi C, Li Q, Jiang Y, Chen X, et al. Integrative analysis of aging-related genes reveals CEBPA as a novel therapeutic target in non-small cell lung cancer. Cancer Cell Int. 2024;24:267.","journal-title":"Cancer Cell Int"},{"key":"8115_CR37","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1038\/s41388-021-01812-7","volume":"40","author":"Y Lv","year":"2021","unstructured":"Lv Y, Wang Y, Song Y, Wang SS, Cheng KW, Zhang ZQ, et al. LncRNA PINK1-AS promotes Galphai1-driven gastric cancer tumorigenesis by sponging microRNA-200a. Oncogene. 2021;40:3826\u201344.","journal-title":"Oncogene"},{"key":"8115_CR38","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13046-023-02711-3","volume":"42","author":"Y Cui","year":"2023","unstructured":"Cui Y, Li J, Zhang P, Yin D, Wang Z, Dai J, et al. B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma. J Exp Clin Cancer Res. 2023;42:146.","journal-title":"J Exp Clin Cancer Res"},{"key":"8115_CR39","doi-asserted-by":"crossref","unstructured":"Kim JH, Choi HS, Lee DS. Primaquine inhibits the endosomal trafficking and nuclear localization of egfr and induces the apoptosis of breast cancer cells by nuclear EGFR\/Stat3-mediated c-Myc downregulation. Int J Mol Sci. 2021;22.","DOI":"10.3390\/ijms222312961"},{"key":"8115_CR40","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1038\/onc.2014.257","volume":"34","author":"D Zhao","year":"2015","unstructured":"Zhao D, Pan C, Sun J, Gilbert C, Drews-Elger K, Azzam DJ, et al. VEGF drives cancer-initiating stem cells through VEGFR-2\/Stat3 signaling to upregulate Myc and Sox2. Oncogene. 2015;34:3107\u201319.","journal-title":"Oncogene"},{"key":"8115_CR41","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.chembiol.2021.10.006","volume":"29","author":"L Sun","year":"2022","unstructured":"Sun L, Yan Y, Lv H, Li J, Wang Z, Wang K, et al. Rapamycin targets STAT3 and impacts c-Myc to suppress tumor growth. Cell Chem Biol. 2022;29:373\u201385. e6.","journal-title":"Cell Chem Biol"},{"key":"8115_CR42","doi-asserted-by":"crossref","unstructured":"Wang YY, Lin SY, Chang CY, Wu CC, Chen WY, Liao SL, et al. Jak2 Inhibitor AG490 Improved poststroke central and peripheral inflammation and metabolic abnormalities in a rat model of ischemic stroke. Antioxid (Basel). 2021;10.","DOI":"10.3390\/antiox10121958"},{"key":"8115_CR43","doi-asserted-by":"publisher","first-page":"7390","DOI":"10.1021\/ja900616b","volume":"131","author":"DI Hammoudeh","year":"2009","unstructured":"Hammoudeh DI, Follis AV, Prochownik EV, Metallo SJ. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J Am Chem Soc. 2009;131:7390\u2013401.","journal-title":"J Am Chem Soc"},{"key":"8115_CR44","doi-asserted-by":"publisher","first-page":"770663","DOI":"10.3389\/fphar.2021.770663","volume":"12","author":"H Tian","year":"2021","unstructured":"Tian H, Ma D, Tan X, Yan W, Wu X, He C, et al. Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review. Front Pharmacol. 2021;12:770663.","journal-title":"Front Pharmacol"},{"key":"8115_CR45","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","volume":"17","author":"F Derakhshan","year":"2022","unstructured":"Derakhshan F, Reis-Filho JS. Pathogenesis of Triple-Negative Breast Cancer. Annu Rev Pathol. 2022;17:181\u2013204.","journal-title":"Annu Rev Pathol"},{"key":"8115_CR46","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12943-020-01259-6","volume":"19","author":"J Li","year":"2020","unstructured":"Li J, Ma M, Yang X, Zhang M, Luo J, Zhou H, et al. Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab. Mol Cancer. 2020;19:142.","journal-title":"Mol Cancer"},{"key":"8115_CR47","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.canlet.2016.03.001","volume":"382","author":"G Judes","year":"2016","unstructured":"Judes G, Rifai K, Daures M, Dubois L, Bignon YJ, Penault-Llorca F, et al. High-throughput\u2009< <\u2009Omics\u2009> >\u2009technologies: New tools for the study of triple-negative breast cancer. Cancer Lett. 2016;382:77\u201385.","journal-title":"Cancer Lett"},{"key":"8115_CR48","doi-asserted-by":"publisher","first-page":"7974","DOI":"10.7150\/thno.45037","volume":"10","author":"SJ Kim","year":"2020","unstructured":"Kim SJ, Ju JS, Kang MH, Eun JW, Kim YH, Raninga PV, et al. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC. Theranostics. 2020;10:7974\u201392.","journal-title":"Theranostics"},{"key":"8115_CR49","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13046-020-01736-2","volume":"39","author":"CA Ciocan-Cartita","year":"2020","unstructured":"Ciocan-Cartita CA, Jurj A, Zanoaga O, Cojocneanu R, Pop LA, Moldovan A, et al. New insights in gene expression alteration as effect of doxorubicin drug resistance in triple negative breast cancer cells. J Exp Clin Cancer Res. 2020;39:241.","journal-title":"J Exp Clin Cancer Res"},{"key":"8115_CR50","doi-asserted-by":"publisher","first-page":"27764","DOI":"10.1074\/jbc.M113.476358","volume":"288","author":"A Abe","year":"2013","unstructured":"Abe A, Takahashi-Niki K, Takekoshi Y, Shimizu T, Kitaura H, Maita H, et al. Prefoldin plays a role as a clearance factor in preventing proteasome inhibitor-induced protein aggregation. J Biol Chem. 2013;288:27764\u201376.","journal-title":"J Biol Chem"},{"key":"8115_CR51","doi-asserted-by":"publisher","first-page":"29794","DOI":"10.1074\/jbc.273.45.29794","volume":"273","author":"K Mori","year":"1998","unstructured":"Mori K, Maeda Y, Kitaura H, Taira T, Iguchi-Ariga SM, Ariga H. MM-1, a novel c-Myc-associating protein that represses transcriptional activity of c-Myc. J Biol Chem. 1998;273:29794\u2013800.","journal-title":"J Biol Chem"},{"key":"8115_CR52","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1177\/2472555220985457","volume":"26","author":"LA Kallal","year":"2021","unstructured":"Kallal LA, Waszkiewicz A, Jaworski JP, Della Pietra A, Berrodin T, Brady P, et al. High-Throughput Screening and Triage Assays Identify Small Molecules Targeting c-MYC in Cancer Cells. SLAS Discov. 2021;26:216\u201329.","journal-title":"SLAS Discov"},{"key":"8115_CR53","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1158\/2159-8290.CD-20-0652","volume":"11","author":"JRP Knight","year":"2021","unstructured":"Knight JRP, Alexandrou C, Skalka GL, Vlahov N, Pennel K, Officer L, et al. MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression. Cancer Discov. 2021;11:1228\u201347.","journal-title":"Cancer Discov"},{"key":"8115_CR54","doi-asserted-by":"publisher","first-page":"394","DOI":"10.18632\/genesandcancer.126","volume":"7","author":"A Rastogi","year":"2016","unstructured":"Rastogi A, Ali A, Tan SH, Banerjee S, Chen Y, Cullen J, et al. Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag. Genes Cancer. 2016;7:394\u2013413.","journal-title":"Genes Cancer"},{"key":"8115_CR55","doi-asserted-by":"crossref","unstructured":"Yesseyeva G, Aikemu B, Hong H, Yu C, Dong F, Sun J, et al. Prefoldin subunits (PFDN1-6) serve as poor prognostic markers in gastric cancer. Biosci Rep. 2020;40.","DOI":"10.1042\/BSR20192712"},{"key":"8115_CR56","doi-asserted-by":"publisher","first-page":"15410","DOI":"10.1038\/s41598-021-94514-9","volume":"11","author":"R Vishnubalaji","year":"2021","unstructured":"Vishnubalaji R, Alajez NM. Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-beta signaling. Sci Rep. 2021;11:15410.","journal-title":"Sci Rep"},{"key":"8115_CR57","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10549-018-4697-y","volume":"169","author":"RLB Costa","year":"2018","unstructured":"Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K\/AKT\/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat. 2018;169:397\u2013406.","journal-title":"Breast Cancer Res Treat"},{"key":"8115_CR58","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.clbc.2022.05.010","volume":"22","author":"H Liu","year":"2022","unstructured":"Liu H, Mei Y, Ma X, Zhang X, Nie W. FRZB is Regulated by the Transcription Factor EGR1 and Inhibits the Growth and Invasion of Triple-Negative Breast Cancer Cells by Regulating the JAK\/STAT3 Pathway. Clin Breast Cancer. 2022;22:690\u20138.","journal-title":"Clin Breast Cancer"},{"key":"8115_CR59","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ymthe.2021.08.026","volume":"30","author":"Y Li","year":"2022","unstructured":"Li Y, Wang Z, Su P, Liang Y, Li Z, Zhang H, et al. circ-EIF6 encodes EIF6-224aa to promote TNBC progression via stabilizing MYH9 and activating the Wnt\/beta-catenin pathway. Mol Ther. 2022;30:415\u201330.","journal-title":"Mol Ther"},{"key":"8115_CR60","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12943-024-02019-6","volume":"23","author":"Y Li","year":"2024","unstructured":"Li Y, Wang Z, Yang J, Sun Y, He Y, Wang Y, et al. CircTRIM1 encodes TRIM1-269aa to promote chemoresistance and metastasis of TNBC via enhancing CaM-dependent MARCKS translocation and PI3K\/AKT\/mTOR activation. Mol Cancer. 2024;23:102.","journal-title":"Mol Cancer"},{"key":"8115_CR61","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13046-020-01800-x","volume":"40","author":"W Xie","year":"2021","unstructured":"Xie W, Zhao H, Wang F, Wang Y, He Y, Wang T, et al. A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt\/beta-catenin signaling pathway. J Exp Clin Cancer Res. 2021;40:30.","journal-title":"J Exp Clin Cancer Res"},{"key":"8115_CR62","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13046-019-1206-z","volume":"38","author":"JJ Qin","year":"2019","unstructured":"Qin JJ, Yan L, Zhang J, Zhang WD. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. J Exp Clin Cancer Res. 2019;38:195.","journal-title":"J Exp Clin Cancer Res"},{"key":"8115_CR63","doi-asserted-by":"publisher","first-page":"116500","DOI":"10.1016\/j.ejmech.2024.116500","volume":"273","author":"L Long","year":"2024","unstructured":"Long L, Xu J, Qi X, Pen Y, Wang C, Jiang W, et al. Discovery of novel small molecules targeting the USP21\/JAK2\/STAT3 axis for the treatment of triple-negative breast cancer. Eur J Med Chem. 2024;273:116500.","journal-title":"Eur J Med Chem"},{"key":"8115_CR64","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1038\/s41388-020-01454-1","volume":"39","author":"D Doheny","year":"2020","unstructured":"Doheny D, Sirkisoon S, Carpenter RL, Aguayo NR, Regua AT, Anguelov M, et al. Combined inhibition of JAK2-STAT3 and SMO-GLI1\/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis. Oncogene. 2020;39:6589\u2013605.","journal-title":"Oncogene"},{"key":"8115_CR65","doi-asserted-by":"crossref","unstructured":"Tolomeo M, Cascio A. The multifaced role of STAT3 in cancer and its implication for anticancer therapy. Int J Mol Sci. 2021;22.","DOI":"10.3390\/ijms22020603"},{"key":"8115_CR66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12967-023-04834-9","volume":"22","author":"E Zhang","year":"2024","unstructured":"Zhang E, Chen Z, Liu W, Lin L, Wu L, Guan J, et al. NCAPG2 promotes prostate cancer malignancy and stemness via STAT3\/c-MYC signaling. J Transl Med. 2024;22:12.","journal-title":"J Transl Med"},{"key":"8115_CR67","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40659-021-00363-1","volume":"54","author":"R Ning","year":"2021","unstructured":"Ning R, Chen G, Fang R, Zhang Y, Zhao W, Qian F. Diosmetin inhibits cell proliferation and promotes apoptosis through STAT3\/c-Myc signaling pathway in human osteosarcoma cells. Biol Res. 2021;54:40.","journal-title":"Biol Res"},{"key":"8115_CR68","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12935-024-03270-z","volume":"24","author":"H Zhou","year":"2024","unstructured":"Zhou H, Li J, He Y, Xia X, Liu J, Xiong H. SLC25A17 inhibits autophagy to promote triple-negative breast cancer tumorigenesis by ROS-mediated JAK2\/STAT3 signaling pathway. Cancer Cell Int. 2024;24:85.","journal-title":"Cancer Cell Int"},{"key":"8115_CR69","first-page":"877","volume":"53","author":"DY Kang","year":"2018","unstructured":"Kang DY, Sp N, Kim DH, Joung YH, Lee HG, Park YM, et al. Salidroside inhibits migration, invasion and angiogenesis of MDA\u2013MB 231 TNBC cells by regulating EGFR\/Jak2\/STAT3 signaling via MMP2. Int J Oncol. 2018;53:877\u201385.","journal-title":"Int J Oncol"},{"key":"8115_CR70","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41419-020-03188-0","volume":"12","author":"Q Wang","year":"2021","unstructured":"Wang Q, Liu J, You Z, Yin Y, Liu L, Kang Y, et al. LncRNA TINCR favors tumorigenesis via STAT3-TINCR-EGFR-feedback loop by recruiting DNMT1 and acting as a competing endogenous RNA in human breast cancer. Cell Death Dis. 2021;12:83.","journal-title":"Cell Death Dis"},{"key":"8115_CR71","doi-asserted-by":"publisher","first-page":"104868","DOI":"10.1016\/j.phrs.2020.104868","volume":"158","author":"M Zhu","year":"2020","unstructured":"Zhu M, Shi X, Gong Z, Su Q, Yu R, Wang B, et al. Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2\/STAT3 and PI3K\/Akt pathways in an EphB4-dependent manner. Pharmacol Res. 2020;158:104868.","journal-title":"Pharmacol Res"},{"key":"8115_CR72","doi-asserted-by":"publisher","first-page":"217354","DOI":"10.1016\/j.canlet.2024.217354","volume":"610","author":"K Yoshimura","year":"2025","unstructured":"Yoshimura K, Zou G, Fan Y, Yamashita K, Wang L, Wu J, et al. HSP90 inhibitor AUY922 suppresses tumor growth and modulates immune response through YAP1-TEAD pathway inhibition in gastric cancer. Cancer Lett. 2025;610:217354.","journal-title":"Cancer Lett"},{"key":"8115_CR73","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1002\/ijc.33485","volume":"148","author":"G Marcion","year":"2021","unstructured":"Marcion G, Hermetet F, Neiers F, Uyanik B, Dondaine L, Dias AMM, et al. Nanofitins targeting heat shock protein 110: An innovative immunotherapeutic modality in cancer. Int J Cancer. 2021;148:3019\u201331.","journal-title":"Int J Cancer"},{"key":"8115_CR74","doi-asserted-by":"crossref","unstructured":"Li SQ, Zhu XR, Liu YY, Chen MB. A novel immunological perspective on female-specific cancers: Exploring the signaling pathways of tertiary lymphoid structures and their clinical applications. Life Sci. 2025:123800.","DOI":"10.1016\/j.lfs.2025.123800"},{"key":"8115_CR75","doi-asserted-by":"publisher","first-page":"107969","DOI":"10.1016\/j.pharmthera.2021.107969","volume":"230","author":"L Zhang","year":"2022","unstructured":"Zhang L, Kuca K, You L, Zhao Y, Musilek K, Nepovimova E, et al. Signal transducer and activator of transcription 3 signaling in tumor immune evasion. Pharmacol Ther. 2022;230:107969.","journal-title":"Pharmacol Ther"},{"key":"8115_CR76","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.canlet.2017.12.003","volume":"415","author":"Y Wang","year":"2018","unstructured":"Wang Y, Shen Y, Wang S, Shen Q, Zhou X. The role of STAT3 in leading the crosstalk between human cancers and the immune system. Cancer Lett. 2018;415:117\u201328.","journal-title":"Cancer Lett"},{"key":"8115_CR77","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"X Jiang","year":"2019","unstructured":"Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18:10.","journal-title":"Mol Cancer"},{"key":"8115_CR78","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41419-023-06230-z","volume":"14","author":"R Huang","year":"2023","unstructured":"Huang R, Wang Z, Hong J, Wu J, Huang O, He J, et al. Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy. Cell Death Dis. 2023;14:703.","journal-title":"Cell Death Dis"},{"key":"8115_CR79","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1038\/s41467-022-31764-9","volume":"13","author":"S Ma","year":"2022","unstructured":"Ma S, Zhao Y, Lee WC, Ong LT, Lee PL, Jiang Z, et al. Hypoxia induces HIF1alpha-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy. Nat Commun. 2022;13:4118.","journal-title":"Nat Commun"},{"key":"8115_CR80","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13046-017-0593-2","volume":"36","author":"X Huang","year":"2017","unstructured":"Huang X, Xie X, Wang H, Xiao X, Yang L, Tian Z, et al. PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a. J Exp Clin Cancer Res. 2017;36:129.","journal-title":"J Exp Clin Cancer Res"},{"key":"8115_CR81","doi-asserted-by":"crossref","unstructured":"Syrnioti A, Petousis S, Newman LA, Margioula-Siarkou C, Papamitsou T, Dinas K, et al. Triple negative breast cancer: molecular subtype-specific immune landscapes with therapeutic implications. Cancers (Basel). 2024;16.","DOI":"10.3390\/cancers16112094"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08115-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08115-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08115-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:02:52Z","timestamp":1777942972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08115-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8115"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08115-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to the Declaration of Helsinki, the Ethics Committee of Jiangsu University has approved this study (approval number: 2025-03-108-H00-K01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have consented to the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No potential conflicts of interest were disclosed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"626"}}